The Peter Attia Drive cover art

The Peter Attia Drive

The Peter Attia Drive

By: Peter Attia MD
Listen for free

About this listen

 The Peter Attia Drive will feature guests and experts that will offer advice and insight to help you optimize performance, health, longevity, critical thinking, and life. It's hosted by Stanford M.D., TED speaker, and longevity expert Dr. Peter Attia, founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City.Copyright © Peter Attia, MD Exercise & Fitness Fitness, Diet & Nutrition Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • #388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

    #388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives
    Apr 20 2026

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter's Weekly Newsletter

    In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.

    We discuss:

    • The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];
    • PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];
    • The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];
    • How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];
    • Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];
    • Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];
    • Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];
    • Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];
    • How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];
    • The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and
    • More.

    Connect With Peter on Twitter, Instagram, Facebook and YouTube
    Show More Show Less
    46 mins
  • #387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

    #387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
    Apr 13 2026
    View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15];How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; andMore. Connect With Peter on Twitter, Instagram, Facebook and YouTube
    Show More Show Less
    22 mins
  • #386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance

    #386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance
    Apr 6 2026

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter's Weekly Newsletter

    In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.

    We discuss:

    • Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];
    • How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];
    • The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];
    • The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];
    • Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];
    • The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];
    • The DO-HEALTH study results: findings, takeaways, and open questions [27:45];
    • The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];
    • The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00];
    • Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and
    • More.

    Connect With Peter on Twitter, Instagram, Facebook and YouTube
    Show More Show Less
    56 mins
All stars
Most relevant
really loved the limitless series so listening to this podcast was great. getting more of Chris and peters insights was very interesting

loved limitless

Something went wrong. Please try again in a few minutes.
The title of this review is not an understatement. Listening to Peter has transformed my life in all ways. I never really grasped the importance of exercise until Attia and have gone from being an exercise avoider to loving exercise and exercising for a minimum of 7+ hours a week. After a life time of serial yo yo dieting, I lost circa 45 pounds which I've maintained for over 2 years. I credit being weight stable at a very healthy weight to understanding it's exercise that is even more crucial to health than nutrition. Thank you Peter.

Peter Attia has transformed my life

Something went wrong. Please try again in a few minutes.
Excellent up to date content backed by solid research papers. Delivered in an informative manner but accepting that some content requires some chewing over and repetition to comprehend adequately.

Pushing Boundaries

Something went wrong. Please try again in a few minutes.
Important information that makes me reflect on my liffe and becoming more mindfully of the world around me that will make me live longer and learn.

Usefull insight on how to live a better life

Something went wrong. Please try again in a few minutes.